Tests Bacillus subtilis capsules alongside infliximab in Crohn's disease
Tests Bacillus subtilis capsules added to infliximab in adults with Crohn's disease.
Plain-language title generated from the registry record
Registry title: Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease
Key facts
- Where
- Changsha, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07123207, who can take part
Where in China
- The Third Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Third Xiangya Hospital of Central South University
- Trial code
- NCT07123207
- Record updated
- 14 August 2025
- Original description
The goal of this clinical trial is to evaluate the effect of supplementing Bacillus subtilis compared to the control group on the efficacy of Infliximab in patients with Crohn's disease, and to summarize the role of supplementing Bacillus subtilis in the treatment of CD patients.Read full original descriptionShow less
The Impact of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease: a Multicenter, Randomized, Single-blind, Blank-controlled Clinical Study
The goal of this clinical trial is to evaluate the effect of supplementing Bacillus subtilis compared to the control group on the efficacy of Infliximab in patients with Crohn's disease, and to summarize the role of supplementing Bacillus subtilis in the treatment of CD patients.
Participants will be randomized into two groups: the Bacillus subtilis supplementation group and the control group. The patients in the Bacillus subtilis supplementation group received oral Bacillus subtilis capsules for 12 weeks. The control group did not receive additional intervention. Follow up once a week, and after the study, patients will come to the hospital to finish the evaluation indicators.
Inclusion: Age ≥ 18 years old, ≤ 75 years old; Patients clinically diagnosed with Crohn's disease shall refer to the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023) for diagnostic criteria; Patients receiving treatment with Infliximab; The patient is currently in the clinical active stage(CDAI≥150 or SES-CD≥3); Agree to participate in this study and sign an informed consent form.
Exclusion: Have participated in any other clinical research within the first month prior to enrollment; Patients with severe active infections in the intestines or other areas that require the use of antibiotics or antiviral drugs; Patients with intestinal tuberculosis, other chronic intestinal infectious diseases, and intestinal malignant tumors; Merge patients with severe mental illness, drug use, alcohol abuse, etc. who are unable to cooperate with the study; The researcher determined that any other disease or condition is not suitable for patients participating in this study; Patients with ALT or AST exceeding the normal upper limit by more than twice, and TBIL exceeding the normal upper limit by more than twice; Patients with creatinine clearance rate less than 60ml/min; The fasting blood glucose of patients with diabetes or screening period exceeds 7.0mmol/L or glycosylated hemoglobin exceeds 6.5%; Participants who meet any of the following criteria are not eligible for inclusion in this study; Pregnant and lactating women.